News & Updates

Show Multimedia Only
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD

Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD

02 Nov 2022 byJairia Dela Cruz

Patients with concomitant chronic kidney disease (CKD) and type 2 diabetes (T2D) who are undergoing mineralocorticoid receptor blockade with finerenone are better protected against pneumonia and COVID-19, according to a secondary analysis of data from the FIDELITY trials.

02 Nov 2022